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Abstract
Introduction Stimulation of beta2-adrenergic receptors (β2-
ARs) inhibits tumor necrosis factor-alpha (TNF-α) release in
monocytes. In septic shock, endogenous catecholamines
induce β2-AR downregulation, leading to an increased TNF-α
release. The aims of this study were to analyze the molecular
mechanisms of β-adrenergic downregulation and to explore
therapeutic interventions with maintained anti-inflammatory
efficacy in septic shock using the inhibition of
phosphodiesterase 4 (PDE4).
Methods We conducted in vitro stimulation of peripheral blood
mononuclear cells of healthy volunteers (n = 20) and patients
with septic shock (n = 20) with lipopolysaccharide (LPS) or
Staphylococcus aureus enterotoxin B (SEB) without or with
isoprenaline, forskolin (an activator of adenylate cyclase), or
ropipram (an inhibitor of PDE4). We also conducted flow
cytometric analysis of Toll-like receptor (TLR) 4 and TLR2
surface expression and intracellular TNF-α production of
untreated and stimulated CD14+ monocytes. Protein expression
of β-ARs, of G proteins, of adenylate cyclase, and of TLRs was
measured by Western blotting.
Results Investigations were done by LPS (100 ng/mL) or SEB
(10 ng/mL) when TLR4 and TLR2 were maximally expressed.
LPS- or SEB-treated CD14+ monocytes of healthy volunteers
were able to produce TNF-α. This effect was attenuated by
isoprenaline, forskolin, or rolipram in a concentration-dependent
manner. In CD14+ monocytes of patients with septic shock, the
anti-inflammatory effect of isoprenaline was completely blunted
whereas efficacy of forskolin and rolipram was maintained.
CD14+ monocytes of healthy volunteers were compared with
patients with septic shock: protein expression of β2-ARs was
reduced and inhibitory G protein was increased, whereas no
changes in adenylate cyclase and stimulatory G protein were
found.
Conclusions In septic shock, the anti-inflammatory effects of
catecholamines are blunted by downregulation of β2-ARs and
upregulation of the inhibitory G protein in CD14+ monocytes.
Beta-adrenergic downregulation is overcome by inhibitors of
PDE4. These results provide a mechanistic rationale for the
therapeutic use of selective PDE4 inhibitors in the treatment of
septic shock.
Introduction
Severe sepsis and septic shock are systemic responses to
infection and represent predominant causes of death in inten-
sive care units [1,2], with the incidence of sepsis steadily
increasing over the past decades [3]. Monocytes are activated
by surface receptors such as Toll-like receptors (TLRs)
through recognition of pathogen-derived exogenous ligands:
lipopolysaccharides (LPSs), Staphylococcus aureus entero-
toxin B (SEB), other peptidoglycans, and oligonucleotides.
TLR-mediated signaling pathways induce proinflammatory
cytokine expression like tumor necrosis factor-alpha (TNF-α)
and interleukin-6, triggering the systemic inflammatory
response syndrome and the development of septic shock
[4,5].
β-AR: beta-adrenergic receptor; AC: adenylate cyclase; Cy5: cyanine 5; EC50: 50% of the maximal effect; FACS: fluorescence-activated cell sorting; 
FITC: fluorescein isothiocyanate; Giα: alpha-subunit of the inhibitory G protein; Gsα: alpha-subunit of stimulatory G protein; LPS: lipopolysaccharide; 
PBMC: peripheral blood mononuclear cell; PDE4: phosphodiesterase 4; PE: phycoerythrin; SEB: Staphylococcus aureus enterotoxin B; TLR: Toll-
like receptor; TNF-α: tumor necrosis factor-alpha.Critical Care    Vol 12 No 6    Link et al.
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It has long been recognized that β-adrenergic stimulation sup-
presses LPS-induced TNF-α release from blood cells in vitro
and in vivo [6] and thus could ameliorate the inflammatory
response. In severe sepsis and septic shock, neuroendocrine
systems are activated. Sympathetic activation is associated
with increasing plasma concentrations of epinephrine and
norepinephrine [7] and desensitization of the β-adrenergic
system (that is, downregulation of β-adrenergic receptor [β-
AR] density as shown for the β1-ARs in chronic heart failure [8-
10]). Also, in patients with septic shock, the hemodynamic
response to β1-AR agonists was impaired, and in peripheral
blood mononuclear cells (PBMCs), a decreased β2-AR-medi-
ated cAMP production was found [11-13].
In septic shock, patients require intravenous catecholamines,
which may aggravate β-adrenergic desensitization, potentially
leading to further deterioration of the hemodynamic situation
and overwhelming PBMC TNF-α release. Thus, an attractive
therapeutic approach to exert cAMP-mediated anti-inflamma-
tory effects despite β-AR desensitization would be to inhibit
phosphodiesterase 4 (PDE4) by rolipram [14,15]. The present
study was designed (a) to analyze whether β-AR-mediated
inhibition of LPS-induced TNF-α expression is blunted in
PBMCs of human patients with septic shock, (b) to clarify
which mechanisms of desensitization are involved, and (c) to
determine whether the PDE4 inhibitor rolipram is able to sup-
press LPS-induced TNF-α expression.
Materials and methods
After approval of the institutional review board and informed
consent of all of the study participants were received, blood
samples were obtained from 20 healthy volunteers without any
signs of infection and from 20 patients with septic shock.
Because of age-related differences in leukocyte function, the
healthy control group was age-matched (median of 49 years
and range of 21 to 75 years). All patients fulfilled criteria of
septic shock defined as sepsis with at least one organ dys-
function and the requirement of catecholamine therapy [16].
Demographic and clinical characteristics of patients are pre-
sented in Table 1.
Cell preparation, stimulation, and culture conditions
PBMCs were isolated with the use of a Ficoll density gradient
(Biochrom, Berlin, Germany) within 30 minutes after collecting
peripheral venous blood from volunteers or septic patients.
Cells were cultured at 3 × 106 cells per milliliter in RPMI 1640
(PAA Laboratories, Cölbe, Germany) supplemented with 5%
fetal calf serum (Biochrom), 2 mmol/L glutamine, and antibiot-
ics. Culture media and all reagents were tested for the
absence of endotoxins. All incubations were carried out in a
humidified incubator at 37°C, 21% O2 and 5% CO2.
PBMCs were analyzed for (a) changes of TLR4 expression in
response to increasing LPS (0.1 to 10,000 ng/mL) and isopre-
naline (0.0001 to 10 μmol/L) concentrations and time
dependency (6, 12, and 24 hours), (b) changes of TLR2
expression in response to increasing SEB (0.1 to 10,000 ng/
mL) and isoprenaline (0.0001 to 10 μmol/L) concentrations
and time dependency (6, 12, and 24 hours), (c) changes of
LPS-mediated TNF-α expression in the absence or presence
of isoprenaline, rolipram, and forskolin (all 0.001 to 10 μmol/
L), and (d) changes of SEB-mediated TNF-α expression in the
absence or presence of isoprenaline, rolipram, and forskolin
(all 0.001 to 10 μmol/L).
Intracellular cytokine measurement by flow cytometry
For cytokine expression, PBMCs were stimulated with LPS
(100 ng/mL) or SEB (10 ng/mL) and reagents simultaneously
Table 1
Patients' demographic data, clinical characteristics, and 
survival
Demographic data
Age in years, median (range) 52 (25 to 73)
Female/male, number 10/10
Septic shock: reasons
Pneumonia 8
Urosepsis 4
Cholangitis 4
Endocarditis 3
Catheter-associated 3
Pathogen
Staphylococcus epidermidis, number 6
Staphylococcus aureus, number 2
Haemophilus influenca, number 4
Enterococcus faecalis, number 3
Escherichia coli, number 3
Pseudomonas aeruginosa, number 2
Severity-of-illness scores
APACHE II score, median (range) 30 (18 to 52)
SAPS II, median (range) 42 (32 to 66)
Catecholamine therapy
Dobutamine, number
Dose in μg/kg per minute (mean ± SD)
20
(6.4 ± 2.9)
Norepinephrine, number
Dose in μg/kg per minute (mean ± SD)
16
(0.2 ± 0.2)
Outcome
ICU mortality rate, number (percentage) 4 (20)
Hospital mortality rate, number (percentage) 5 (25)
APACHE, Acute Physiology and Chronic Health Evaluation; ICU, 
intensive care unit; SAPS, Simplified Acute Physiology Score; SD, 
standard deviation.Available online http://ccforum.com/content/12/6/R159
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and incubated for a total of 24 hours. Initially, Brefeldin A (10
μg/mL) (Sigma-Aldrich, Munich, Germany) was added to
block extracellular secretion of cytokines. Cell fixation was
done with 2 mM EDTA (ethylenediaminetetraacetic acid) for
15 minutes for planned measurement of cytokine expression
after 6 hours. Cell membranes were reversibly permeabilized
with Saponine (0.1%) (Sigma-Aldrich) in phosphate-buffered
saline containing 5% milk powder and 0.1% bovine serum
albumin (Sigma-Aldrich). Cell surface markers and intracellular
cytokines were labelled with mouse anti-human antibodies
conjugated to fluorescent dyes at saturating concentrations in
permeabilization buffer. For staining of the cell surface markers
of monocytes, we used anti-CD14-PE-Cy5 (anti-CD14-phyco-
erythrin-cyanine 5), anti-TLR4-FITC (anti-TLR4-fluorescein iso-
thiocyanate), and anti-TLR2-FITC. For staining of intracellular
monocyte cytokines, we used anti-TNF-α-FITC. After 45 min-
utes of incubation at room temperature, cells were washed
three times in permeabilization buffer and twice in fluores-
cence-activated cell sorting (FACS) buffer. Subsequently,
stained antigens were fixed with 1% paraformaldehyde.
Measurements were performed on a Becton Dickinson FACS-
can flow cytometer (Becton Dickinson, Heidelberg, Germany)
and the Cellquest software system (Becton Dickinson, Heidel-
berg, Germany). Monocytes were identified by forward and
sideward scatter and CD14 positivity, and 10,000 events of
CD14+ monocytes were gated. The data are shown as median
fluorescence intensities of TNF-α-producing CD14+ mono-
cytes. This method allows a more complete analysis of the
functional activity on a single-cell level compared with conven-
tional methods, as described previously [17].
Western blotting
Monocytes were isolated from PBMCs by magnetic cell sort-
ing using microbeads in accordance with the instructions of
the manufacturer (Dynabeads Monocyte; Invitrogen Corpora-
tion, Carlsbad, CA, USA). Isolated monocytes are bead- and
antibody-free with a purity of CD14+ monocytes of 95%.
These cells were separated in cytosol and membrane proteins,
containing equal aliquots of denatured protein (50 μg). Non-
specific binding was blocked by incubation with 5% nonfat dry
milk for 1 hour at room temperature. Immunoblotting was per-
formed using the following monoclonal antibodies: β2-AR,
adenylate cyclase (AC), and α-subunits of stimulatory (Gsα)
and inhibitory (Giα) G proteins. Equal loading of total protein
was controlled by Poinceau red staining (Serva Electrophore-
sis, Heidelberg, Germany). The immunoreactive bands were
quantified by two-dimensional densitometry using Multianalyst
software (Bio-Rad Laboratories, München, Germany).
Reagents and materials
Standard reagents of the highest available quality were used.
LPS (serotype Escherichia coli 055:B5), SEB (fragment 150–
161), isoprenaline, and forskolin were purchased from Sigma-
Aldrich. Rolipram from A.G. Scientific (San Diego, CA, USA)
was used. The drug concentrations that we used had no cyto-
toxic influence on the measured PBMCs. The following mono-
clonal antibodies were used: anti-CD14 PE-Cy5-labelled
(clone RMO52, lot 06; Beckman Coulter, Krefeld, Germany),
anti-TNF-α FITC-labelled (clone MAb11, lot 28687; BD
Pharmingen, San Diego, CA, USA), anti-TLR4 (clone
76B357.1, lot 445414; Abcam, Cambridge, UK), anti-TLR2
(clone T2.5, lot 526240; Abcam), anti-AC (rabbit polyclonal
IgG), anti-β2-AR (rabbit polyclonal IgG) from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA, USA), anti-Gαs (rabbit poly-
clonal IgG) from Upstate Biotechnology (Lake Placid, NY,
USA), and anti-Gαi2 generated as described previously [18].
Statistics
Data were calculated as mean ± standard error of the mean
and were analyzed using one-way analysis of variance. If vari-
ances differed significantly, the Mann-Whitney test was used.
A P value of less than 0.05 was considered significant. Con-
centrations inducing 50% of the maximal effect (EC50) were
calculated using GraphPad Prism software (GraphPad Soft-
ware, Inc., San Diego, CA, USA).
Results
Toll-like receptor surface expression on CD14+ 
monocytes of healthy volunteers
To investigate whether TLRs could participate in the activation
of normal monocytes, we analyzed TLR4 and TLR2 expression
on CD14+ monocytes after stimulation with increasing doses
of LPS or SEB. Cytometric analysis of TLR4 and TLR2 protein
expression of untreated monocytes revealed a constitutive
expression of both receptors (Figures 1 and 2). Treatment with
LPS induced a significant upregulation of TLR4 expression
even at low LPS concentrations, achieving a submaximal
expression at 100 ng/mL (Figure 1a). CD14+  monocytes
treated with increasing LPS concentrations had stimulatory
effects of the TLR4 surface expression with an EC50 value of
10 ng/mL. Therefore, all further investigations were done by
100 ng/mL LPS when TLR4 was maximally expressed. During
a continuous LPS stimulation (100 ng/mL), TLR4 expression
was significantly increased within 6 hours and the expression
remained stable between 6 and 24 hours (Figure 1b). Treat-
ment with isoprenaline did not alter the expression of TLR4
surface expression (Figure 1c).
Treatment with SEB induced no relevant changes of TLR2
expression even at low and high concentrations (Figure 2a). All
further investigations were done by 10 ng/mL SEB when
TLR2 was maximally expressed. During a continuous SEB
stimulation (10 ng/mL), TLR2 expression remained
unchanged between 6 and 24 hours (Figure 2b). Treatment
with isoprenaline did not alter the expression of TLR2 surface
expression (Figure 2c).Critical Care    Vol 12 No 6    Link et al.
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Inhibition of LPS-/SEB-mediated tumor necrosis factor-
alpha expression in CD14+ monocytes of healthy 
volunteers
Incubation of PBMCs from healthy volunteers with LPS for 24
hours increased the expression of TNF-α in a concentration-
dependent manner. At 100 ng/mL of LPS, 72.3% ± 3.5% of
CD14+ monocytes produced TNF-α. Nonselective β-AR stim-
ulation with isoprenaline (coincubation with 1 μmol/L) sup-
pressed this maximal LPS-induced TNF-α expression up to
40% ± 4.5%. This inhibitory effect of isoprenaline on TNF-α
expression was concentration-dependent with an EC50 value
of 0.1 μmol/L. Also, the selective inhibition of PDE4 with rol-
ipram suppressed TNF-α expression up to 58% ± 4.5% and
the direct activation of AC with forskolin suppressed TNF-α
expression up to 75% ± 3.8% (Figure 3a).
Incubation of PBMCs from healthy volunteers with SEB for 24
hours increased the expression of TNF-α in a concentration-
dependent manner. At 10 ng/mL of SEB, 75.1% ± 3.5% of
CD14+ monocytes produced TNF-α. Nonselective β-AR stim-
ulation with isoprenaline (1 μmol/L) suppressed this maximal
SEB-induced TNF-α expression up to 25% ± 4.5%. Also, the
selective inhibition of PDE4 with rolipram suppressed TNF-α
expression up to 75% ± 5.5% and the direct activation of AC
with forskolin suppressed TNF-α expression up to 85% ±
4.5% (Figure 3b).
Beta-adrenergic downregulation on CD14+ monocytes in 
patients with septic shock
Detailed patient characteristics and critical illness scores are
presented in Table 1. All patients received intravenous cate-
cholamines for hemodynamic stabilization. The LPS-mediated
TNF-α e x p r e s s i o n  i n  C D 1 4 +  monocytes of these patients
could not be suppressed by isoprenaline, while forskolin and
rolipram inhibited the TNF-α expression in these CD14+ mono-
cytes (n = 20, P < 0.001, Figure 4). These data are an indirect
piece of evidence that β-ARs could be downregulated in
CD14+ monocytes of patients with septic shock compared
with healthy controls. To elucidate the detailed mechanism of
β-adrenergic downregulation, Western blot analysis of β2-
Figure 1
Modulation of Toll-like-receptor 4 (TLR4) surface expression on CD14+ monocytes of healthy volunteers (n = 20) Modulation of Toll-like-receptor 4 (TLR4) surface expression on CD14+ monocytes of healthy volunteers (n = 20). Responses to (a) increas-
ing concentrations of lipopolysaccharide (LPS), (b) time dependency under continuous LPS stimulation (100 ng/mL), and (c) increasing concentra-
tions of isoprenaline are shown. TLR4 expression was measured by flow cytometry, and histograms of median fluorescence intensity (MFI) and 
averages with standard error of the mean from all probands are shown. FITC, fluorescein isothiocyanate.Available online http://ccforum.com/content/12/6/R159
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ARs, AC, and Gsα and Giα were performed. In CD14+ mono-
cytes of patients with septic shock, protein expression of β2-
ARs was downregulated by 31% ± 11% (P < 0.001) whereas
expression of Giα was upregulated by 44% ± 17% (P  <
0.001) compared with healthy controls (Figure 5). In contrast,
expressions of Gsα and AC were unchanged.
Discussion
The main findings of the study are that, in CD14+ monocytes
of patients with septic shock, downregulation of β2-ARs and
upregulation of Giα induce β-adrenergic desensitization. This
blunts the catecholamine-induced suppression of LPS-
induced or SEB-induced TNF-α release and thus may aggra-
vate the proinflammatory response in septic shock. Since ex
vivo  incubation with LPS and isoprenaline reproduced β-
adrenergic desensitization in monocytes of healthy volunteers,
elevated plasma concentrations of catecholamines and LPS
may contribute to β-adrenergic desensitization in these
patients in vivo. Furthermore, the anti-inflammatory response
of the PDE4 inhibitor rolipram was maintained, providing a
mechanistic rationale for the use of PDE4 inhibitors in PBMCs
of patients with septic shock.
In agreement with previous studies [6,12], β-adrenergic stim-
ulation suppressed the LPS-induced TNF-α expression in a
concentration-dependent manner in CD14+  monocytes of
healthy volunteers. This effect was mediated by β2-ARs, but
not β1-ARs, confirming previous observations in human mac-
rophages [19]. Similarly, direct activation of AC by forskolin or
inhibition of PDE4 with rolipram reduced LPS-induced TNF-α
expression.
Figure 2
Modulation of Toll-like-receptor 2 (TLR2) surface expression on CD14+ monocytes of healthy volunteers (n = 10) Modulation of Toll-like-receptor 2 (TLR2) surface expression on CD14+ monocytes of healthy volunteers (n = 10). Responses to (a) increas-
ing concentrations of Staphylococcus aureus enterotoxin B (SEB), (b) time dependency under continuous SEB stimulation (10 ng/mL), and (c) 
increasing concentrations of isoprenaline are shown. TLR2 expression was measured by flow cytometry, and histograms of median fluorescence 
intensity (MFI) and averages with standard error of the mean from all probands are shown. FITC, fluorescein isothiocyanate.Critical Care    Vol 12 No 6    Link et al.
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Figure 3
Suppression of lipopolysaccharide (LPS)-mediated or Staphylococcus aureus enterotoxin B (SEB)-mediated tumor necrosis factor-alpha (TNF-α)  expression in CD14+ monocytes of healthy volunteers Suppression of lipopolysaccharide (LPS)-mediated or Staphylococcus aureus enterotoxin B (SEB)-mediated tumor necrosis factor-alpha 
(TNF-α) expression in CD14+ monocytes of healthy volunteers. Suppression of LPS-mediated (100 ng/mL) (a) or SEB-mediated (10 ng/mL) (b) 
TNF-α expression in CD14+ monocytes of healthy volunteers (n = 20) in a concentration-dependent manner by isoprenaline, rolipram, and forskolin 
(all 0.001 to 10 μmol/L) is shown. TNF-α expression was measured by flow cytometry, and histograms of median fluorescence intensity (MFI) and 
averages with standard error of the mean from all probands are shown. FITC, fluorescein isothiocyanate.Available online http://ccforum.com/content/12/6/R159
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An important observation of the present study is that, in
CD14+ monocytes from patients with septic shock, β-AR-
mediated suppression of TNF-α expression was completely
abrogated. Previously, Bergmann and colleagues [12]
observed that, in the whole blood of patients with septic
shock, the epinephrine-induced suppression of LPS-mediated
TNF-α release was reduced by only approximately 50% com-
pared with healthy volunteers. The reason for this discrepancy
remains unclear. The use of epinephrine or norepinephrine
instead of isoprenaline is unlikely to account for this difference
since it has been shown previously that epinephrine-induced
stimulation of α-ARs does not mediate the suppression of
TNF-α release [6]. However, while in our study the use of
FACS analysis allowed the estimation of TNF-α expression
specifically in CD14+ monocytes, the study of Bergmann and
colleagues [12] assessed TNF-α release into the blood from a
large variety of potential sources without discrimination of the
underlying cell types. Thus, in their study, sources other than
monocytes may have contributed to residual suppression of
LPS-induced TNF-α release.
Previous studies have not fully resolved the precise mecha-
nisms for β-adrenergic desensitization of the anti-inflammatory
effect of catecholamines in septic shock. Bernardin and col-
leagues [13] observed that, in PBMCs of patients with severe
sepsis, production of isoprenaline-, NaF-, and forskolin-
induced cAMP was each substantially blunted, suggesting
heterologous desensitization of the β-adrenergic pathway with
defects at the level of AC. In contrast, we did not observe any
changes in the protein expression of AC or Gs, but downreg-
ulation of β2-AR and upregulation of Giα. Upregulation of Giα is
in agreement with our previous observation of upregulated Giα
expression in human myocardium from patients with septic
shock [10]. Importantly, the changed expression of β-adrener-
gic signaling components was in concert with the functional
effects since both forskolin- and rolipram-induced suppres-
sions of LPS-induced TNF-α release were maintained. These
data clearly argue against defects at the level of AC in PBMCs
of patients with septic shock, as suggested by Bernardin and
colleagues [13].
During septic shock, LPS-mediated or SEB-mediated TNF-α
release and elevated catecholamines aggravate β-adrenergic
desensitization, and a vicious cycle of unopposed (catecho-
lamine-refractory) inflammation may develop. The mechanisms
of β-adrenergic downregulation in septic shock are of particu-
lar relevance for the development of therapeutic strategies. In
animal models of septic shock, treatment with the PDE4 inhib-
itor rolipram or transgenic ablation of PDE4B [15] ameliorated
the inflammatory response of PBMCs and improved survival.
However, PDE4 inhibitors have not been tested in humans
with septic shock yet, and results from animal models may not
be readily extrapolated to the human situation. According to
the data of Bernardin and colleagues [13], who found heterol-
ogous desensitization at the level of AC, one could have
expected reduced anti-inflammatory efficacy of rolipram in
PBMCs of septic patients. Conversely, in our study,
unchanged AC expression and maintained anti-inflammatory
efficacy of rolipram provide a mechanistic rationale for the use
of PDE4 inhibitors in patients with septic shock. Our findings
are limited by missing data about levels of PDE4 (or PDE4
activity) in CD14+  monocytes from control subjects and
patients with sepsis; these data would strengthen the conclu-
sion that inhibition of PDE4 activity is a potential treatment for
sepsis. The clinical use of PDE4 inhibitors is currently limited
to patients with depression [20], chronic obstructive pulmo-
nary disease [21,22], and allergic asthma [23].
Conclusion
This study demonstrates that, in septic shock, the anti-inflam-
matory effects of catecholamines are blunted by downregula-
tion of β2-ARs and upregulation of the inhibitory G proteins in
CD14+ monocytes. Beta-adrenergic downregulation is over-
come by inhibitors of PDE4. These results provide a mechanis-
tic rationale for the therapeutic use of selective PDE4
inhibitors in the treatment of septic shock. Trials to evaluate
the efficacy of PDE4 inhibition in septic shock are warranted.
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Figure 4
Lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α)  expression in CD14+ monocytes of patients with septic shock and  healthy controls Lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha 
(TNF-α) expression in CD14+ monocytes of patients with septic 
shock and healthy controls. LPS-induced (100 ng/mL) TNF-α expres-
sion in CD14+ monocytes of patients with septic shock (n = 20) and 
healthy controls (n = 20) in the absence (Con) and presence of isopre-
naline (Iso), forskolin (Forsk), or rolipram (Roli) (all 1 μmol/L). *P < 0.05 
versus respective control. §P < 0.05 versus Iso in healthy volunteers 
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